MHRA seeks school access to spare adrenaline nasal sprays for anaphylaxis
The MHRA has opened a UK-wide consultation on whether schools should be allowed to purchase and keep spare adrenaline nasal sprays for emergency use in children with severe allergies. The proposal would add a new option for schools already permitted to hold spare adrenaline auto-injectors, extending emergency preparedness as newer needle-free products enter clinical practice.
Around 8% of children and young people in the UK have a food allergy, and a substantial share of severe reactions occur in school. In that setting, minutes matter. Anaphylaxis is a rapidly progressive, potentially fatal allergic emergency, and adrenaline remains the first-line treatment because it reverses airway swelling, vasodilation, and cardiovascular collapse more effectively than antihistamines or steroids can.
The consultation reflects a broader regulatory question: how quickly should school medicine policies adapt when the delivery route changes but the active emergency treatment remains adrenaline? A nasal spray may improve acceptability for some staff and may be easier to deploy in a crisis, particularly when a child is distressed, faint, or resistant to injections. In practice, the policy debate is not about replacing adrenaline. It is about whether schools should be allowed to keep a second, non-needle backup that could be easier to administer during a time-critical event.
Schools would not be required to stock a specific brand or product. Under the proposal, they could choose whether to hold auto-injectors, nasal sprays, or both, while the expectation that children carry their own prescribed adrenaline medicine would remain in place. The emergency stock held at school would function as backup therapy, not as a substitute for a pupil’s personal prescription.
Emergency treatment rules would stay in place
Existing safeguards would remain unchanged. Emergency adrenaline could only be given to children known to be at risk of anaphylaxis, and only by appropriately trained school staff. That framework matters because the safe use of adrenaline depends on recognition, prompt action, and a clear policy for who can administer the medicine and when.
Needle-free delivery may reduce hesitation in some settings, especially among staff who are trained but uneasy about injections. In anaphylaxis, hesitation can be dangerous. Airway compromise, hypotension, and shock can unfold quickly, and the therapeutic window is narrow. A school system that keeps more than one delivery option available may be better positioned to act when the child’s own medicine is unavailable, damaged, expired, or inaccessible.
The consultation also asks whether legislation should adopt broader terminology for self-administered adrenaline products that may become available in future. In regulatory terms, that approach would create more flexibility for new authorised products without requiring a fresh legislative amendment each time a new device reaches the market. For families, schools, and clinicians, the practical value lies in avoiding delays that can leave emergency policy trailing behind medicine development.
Why schools are central to anaphylaxis preparedness
Serious allergic reactions at school are not rare enough to be treated as theoretical. The school day concentrates exposure to meals, snacks, shared equipment, social contact, and unpredictable allergen encounters. For children with known allergy, the school environment can be one of the few places where an emergency unfolds outside parental supervision, which is why safety policies, staff training, and rapid access to adrenaline have become central to allergy management.
Julian Beach, the MHRA executive director for operations, framed the proposal as a way to ensure access to medicines in an emergency while keeping safeguards intact. The agency is also inviting input from teachers, healthcare professionals, parents, carers, and people at risk of anaphylaxis. That breadth is important because implementation in schools depends on more than regulatory permission. It depends on whether staff understand the product, whether storage and training are workable, and whether school policies remain simple enough to use in a crisis.
Amena Warner of Allergy UK said a needle-free device administered into the nose could help reduce worry and give parents, children, and schools more confidence in prompt treatment. The argument carries clinical weight. When people are anxious about using a device, they may delay action, and delay is the enemy in anaphylaxis. A more intuitive route of administration may increase the likelihood that emergency adrenaline is actually delivered when symptoms begin.
Training, clarity, and stock management will decide whether the policy works
Paul Whiteman of NAHT stressed that any proposal must be safe, practical, and properly supported, with clear guidance and training for staff. That focus is justified. A school can only use emergency medicine effectively if staff know how to recognise the signs of anaphylaxis, retrieve the medication quickly, and administer it without confusion over product type or eligibility.
Prof Adam Fox of the National Allergy Strategy Group said the obligation for schools to keep spare adrenaline pens, alongside allergy safety policies and training, has been a major advance for pupils with allergy. He also warned against confusion or unintended consequences if newer treatment options are added. That warning should not be dismissed. Expanding product choice can improve access, but it can also create uncertainty if schools are asked to manage multiple devices without plain guidance on storage, use, and replacement.
A single-sentence reality anchors the whole proposal: a school emergency supply only helps if staff can use it instantly.
The consultation runs for eight weeks and is open to schools, staff, parents, carers, healthcare professionals, and anyone with an interest in emergency treatment for anaphylaxis. The first phase of Benedict’s Law brought stronger allergy-safety requirements for schools in England into force in September 2026, and this consultation now tests whether emergency stock rules should evolve alongside new adrenaline products.
The central question is therefore operational rather than abstract. If schools are to hold adrenaline nasal sprays, the final framework will need to preserve fast access, avoid product confusion, and keep the child’s own prescribed medicine at the center of care. The consultation will show whether the current school model can absorb a new delivery route without weakening the simple message that saves lives: recognize anaphylaxis early and give adrenaline immediately.